EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function

Hiroki Nobayashi iD, Michihiro Satoh iD, Takuo Hirose iD, Shingo Nakayama iD, Yutaro Iwabe iD, Hideaki Hashimoto iD, Takahisa Murakami iD, Kouji Okada iD, Takefumi Mori iD, Hirohito Metoki iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70625 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hiroki Nobayashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Proteinuria, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS), The Medical Research Encouragement Prize of the Japan Medical Association, Kowa Life Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To compare the effects of individual SGLT2 inhibitors on preventing new‐onset proteinuria in patients with type 2 diabetes and preserved kidney function. Materials and Methods A target trial emulation was performed using commercially available databases, including health checkups and claims data, between April 1, 2014 and March 31, 2023. Patients with type 2 diabetes (HbA1c ≥ 6.5%, use of antidiabetic drugs, and/or disease codes of type 2 diabetes) and preserved kidney function (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m 2 , urinary protein < 1+ and without past history of chronic kidney disease) were included. We compared the risk of new‐onset proteinuria among new users of empagliflozin, dapagliflozin and canagliflozin using the inverse probability of treatment weighting to adjust for baseline confounders and the inverse probability of censoring weighting to account for loss to follow‐up.

Results

The mean age was 67.5 ± 10.3 years, and 60% were men. The mean HbA1c level and eGFR were 7.56% ± 1.32% and 75.0 ± 8.0 mL/min/1.73 m 2 , respectively. During the median follow‐up of 522 [263–925] days, new‐onset proteinuria occurred in 43, 66 and 48 empagliflozin, dapagliflozin and canagliflozin users, respectively. Dapagliflozin showed a higher risk of new‐onset proteinuria (hazard ratio [HR], 1.64; 95% confidence interval [CI], 1.15–2.33) than empagliflozin, particularly in men (HR, 2.34; 95% CI, 1.53–3.58) ( p for heterogeneity < 0.01).

Conclusions

Empagliflozin was associated with a lower risk of new‐onset proteinuria compared with dapagliflozin. These findings underscore the importance of individualised SGLT2 inhibitor selection but require confirmation in randomised controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsProteinuriaDiabetic NephropathiesHumansMaleCanagliflozinBenzhydryl CompoundsGlucosidesAgedFemaleMiddle AgedGlomerular Filtration RateKidney

Stichwörter der Autor:innen

SGLT2 inhibitordatabase researchdiabetic nephropathypharmaco‐epidemiologyreal‐world evidence

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCanagliflozinBenzhydryl CompoundsGlucosidesdapagliflozinempagliflozin

Autor:innen und Institutionen

  • Division of Public Health, Hygiene and Epidemiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
  • Department of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
  • Division of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
  • Division of Clinical Pharmaceutics and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

ORCID-Profile: Hiroki Nobayashi, Michihiro Satoh, Takuo Hirose, Shingo Nakayama, Yutaro Iwabe, Hideaki Hashimoto, Takahisa Murakami, Kouji Okada, Takefumi Mori, Hirohito Metoki

Förderung

  • Grants-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (JSPS)
  • The Medical Research Encouragement Prize of the Japan Medical Association
  • Kowa Life Science Foundation
  • Japan Society for the Promotion of Science

Zitieren

APA

Nobayashi, H., Satoh, M., Hirose, T., Nakayama, S., Iwabe, Y., Hashimoto, H., Murakami, T., Okada, K., Mori, T., & Metoki, H. (2026). Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70625

Vancouver

Nobayashi H, Satoh M, Hirose T, Nakayama S, Iwabe Y, Hashimoto H, et al. Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70625

BibTeX
@article{Nobayashi2026,
  author = {Nobayashi, Hiroki and Satoh, Michihiro and Hirose, Takuo and Nakayama, Shingo and Iwabe, Yutaro and Hashimoto, Hideaki and Murakami, Takahisa and Okada, Kouji and Mori, Takefumi and Metoki, Hirohito},
  title = {Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70625}
}
Kostenlos starten →